国家科技部中国科技论文统计源期刊   中国科技核心期刊   WHO西太平洋地区医学索引(WPRIM)收录期刊   湖北优秀期刊
《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>
28例GLP-1受体激动药不良反应/事件分析
Analysis of Adverse Reactions/events of GLP-1 Agonist Preparation Based on 28 Case Reports
  
DOI:
中文关键词:  GLP-1受体激动药  药品不良反应/事件  病例报道  文献综述
英文关键词:GLP-1 agonist preparation  Adverse drug reaction/event  Case reports  Literature review
基金项目:
作者单位
刘杨从1 文煜2 刘明3 徐宏峰1 张建波1 张韶辉1 1.武汉市第一医院药学部 武汉 4300222.武汉音乐学院医疗中心3.北京大学深圳医院 
摘要点击次数: 1148
全文下载次数: 1112
中文摘要:
      摘 要 目的:探讨GLP 1受体激动药不良反应/事件(ADR/ADE)的发生特点。方法:计算机检索CNKI、万方数据、PubMed等数据库,对艾塞那肽、利拉鲁肽、贝那鲁肽、利司那肽、阿必鲁肽、度拉糖肽、索马鲁肽等7种GLP 1受体激动药所致ADR/ADE个例报道文献进行整理分析,分别统计ADR/ADE的患者因素、药物因素和ADR/ADE相关特征等信息。结果:收集文献31篇,获取病例32例,剔除3例用药差错事件,1例阴性报道,纳入分析报道28例。GLP 1受体激动药ADR/ADE女性多于男性,ADR/ADE发生多发生在用药后2个月内,主要涉及消化系统、泌尿生殖系统、皮肤及其附件系统等,其中以胰腺炎与急性肾损伤较为严重。肾功能不全、合并使用血管紧张素受体抑制药±利尿药者可能是急性肾损伤的危险因素,可能机制为严重呕吐、脱水导致低血压、肾血流量不足所致。结论:GLP 1受体激动药较为安全,对于有胰腺炎及急性肾损伤高危因素者用药前2个月内,药师应加强监护与随访,注意患者有无腹痛、严重呕吐、脱水、无尿等症状,以防严重ADR/ADE发生。
英文摘要:
      ABSTRACT Objective: To explore the characteristics of adverse drug reactions/events induced by GLP 1 agonist preparation. Methods:Using computer retrieval the database such as CNKI, Wanfang, PubMed, etc, the adverse reactions/events of GLP 1 agonist preparation were collected and analyzed, including exenatide,liraglutide, albiglutide, dulaglutide, benalutide, semaglutide. The patient factors, medicine factors and ADR/ADE relevant characteristics were examined respectively. Results: 31 articles and 32 cases were collected. 3 medication error events were removed and 1 case report was negative, 28 cases were included in the review analysis. It showed that the ADR/ADE of GLP 1 agonist preparation in women more than men, the majority adverse reactions occurred in the first two months after medication, ADR/ADE involving was major in digestive system,urogenital system and skin accessories. The most notable ADRs were pancreatitis and acute kidney injury. Renal insufficiency, or combined with ARBs±diuretics might be a risk factor for acute renal injury, possibly due to severe vomiting and dehydration leading to hypotension and insufficient renal blood flow. Conclusion:GLP 1 agonist preparation was safe, for those with high risk factors of pancreatitis and acute kidney injury, the pharmacist should strengthen the monitoring and follow up, and pay attention to the symptoms of abdominal pain, severe vomiting, dehydration and no urine, to avoid serious adverse events.
查看全文  查看/发表评论  下载PDF阅读器
关闭